BeiGene (BGNE) Financial Analysis & Valuation | Quarter Chart
BeiGene (BGNE)
BGNEPrice: $184.71
Fair Value: 🔒
🔒score
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to ... more
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and comme... more
Description
Shares
| Market Cap | $20.21B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | John V. Oyler |
| IPO Date | 2016-02-03 | CAGR | 0.7% |
| Employees | 10,600 | Website | www.beigene.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BGNE chart loading...
Fundamentals
Technicals
| Enterprise Value | $18.20B | P/E Ratio | -22.55 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 7.36 | P/B Ratio | 0.69 |
| P/CF Ratio | 4.59 | P/FCF Ratio | 203.8 |
| EPS | $-8.19 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 47.33% | Gross Margin | 0.86% |
| Operating Margin | -0.02% | Profit Margin | -0.04% |
| ROE | -0.05% | ROA | -0.03% |
| ROCE | -0.02% | Current Ratio | 1.95 |
| Quick Ratio | 1.72 | Cash Ratio | 1.25 |
| Debt/Equity | 0.27 | Interest Coverage | — |
| Altman Z Score | 3.98 | Piotroski Score | 4 |